Ardelyx (ARDX) Projected to Post Earnings on Thursday

Ardelyx (NASDAQ:ARDX) is anticipated to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Ardelyx to announce earnings of ($0.05) per share and revenue of $121.6710 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Ardelyx Stock Up 0.6%

Shares of NASDAQ:ARDX opened at $5.01 on Wednesday. The company has a quick ratio of 3.28, a current ratio of 3.49 and a debt-to-equity ratio of 1.37. The business has a fifty day moving average of $5.47 and a two-hundred day moving average of $6.12. The stock has a market cap of $1.24 billion, a P/E ratio of -21.78 and a beta of 0.70. Ardelyx has a 52-week low of $4.71 and a 52-week high of $8.40.

Wall Street Analysts Forecast Growth

ARDX has been the topic of several analyst reports. Zacks Research lowered Ardelyx from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Weiss Ratings lowered shares of Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 29th. Finally, LADENBURG THALM/SH SH started coverage on shares of Ardelyx in a research report on Tuesday, June 16th. They set a “buy” rating and a $16.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $16.10.

Insider Activity at Ardelyx

In related news, insider Mike Kelliher sold 7,248 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total transaction of $45,444.96. Following the completion of the transaction, the insider owned 357,418 shares of the company’s stock, valued at approximately $2,241,010.86. This trade represents a 1.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Eric Duane Foster sold 7,998 shares of Ardelyx stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total transaction of $50,147.46. Following the completion of the sale, the insider owned 417,972 shares of the company’s stock, valued at $2,620,684.44. This trade represents a 1.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 24,572 shares of company stock worth $154,066. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. State of Wyoming acquired a new stake in shares of Ardelyx in the second quarter valued at $61,000. Osaic Holdings Inc. lifted its stake in Ardelyx by 28.2% during the 2nd quarter. Osaic Holdings Inc. now owns 16,854 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 3,709 shares in the last quarter. Focus Partners Wealth acquired a new position in Ardelyx during the 1st quarter worth about $72,000. Jain Global LLC purchased a new position in Ardelyx during the 3rd quarter valued at about $74,000. Finally, WINTON GROUP Ltd purchased a new position in Ardelyx during the 4th quarter valued at about $79,000. 58.92% of the stock is currently owned by institutional investors and hedge funds.

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.